GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Plans » Zhejiang Chemsyn Pharm Co Ltd (BJSE:870656) » Definitions » Cash-to-Debt

Zhejiang Chemsyn Pharm Co (BJSE:870656) Cash-to-Debt : No Debt (1) (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Zhejiang Chemsyn Pharm Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Zhejiang Chemsyn Pharm Co's cash to debt ratio for the quarter that ended in Mar. 2024 was No Debt (1).

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Zhejiang Chemsyn Pharm Co could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Zhejiang Chemsyn Pharm Co's Cash-to-Debt or its related term are showing as below:

BJSE:870656' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.95   Med: No Debt   Max: No Debt
Current: No Debt

During the past 10 years, Zhejiang Chemsyn Pharm Co's highest Cash to Debt Ratio was No Debt. The lowest was 2.95. And the median was No Debt.

BJSE:870656's Cash-to-Debt is ranked better than
95.24% of 21 companies
in the Healthcare Plans industry
Industry Median: 1.77 vs BJSE:870656: No Debt

Zhejiang Chemsyn Pharm Co Cash-to-Debt Historical Data

The historical data trend for Zhejiang Chemsyn Pharm Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Zhejiang Chemsyn Pharm Co Cash-to-Debt Chart

Zhejiang Chemsyn Pharm Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only No Debt No Debt No Debt 14.06 No Debt

Zhejiang Chemsyn Pharm Co Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt No Debt

Competitive Comparison of Zhejiang Chemsyn Pharm Co's Cash-to-Debt

For the Healthcare Plans subindustry, Zhejiang Chemsyn Pharm Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Chemsyn Pharm Co's Cash-to-Debt Distribution in the Healthcare Plans Industry

For the Healthcare Plans industry and Healthcare sector, Zhejiang Chemsyn Pharm Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Zhejiang Chemsyn Pharm Co's Cash-to-Debt falls into.



Zhejiang Chemsyn Pharm Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Zhejiang Chemsyn Pharm Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Zhejiang Chemsyn Pharm Co had no debt (1).

Zhejiang Chemsyn Pharm Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Zhejiang Chemsyn Pharm Co had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang Chemsyn Pharm Co  (BJSE:870656) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Zhejiang Chemsyn Pharm Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Zhejiang Chemsyn Pharm Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Chemsyn Pharm Co (BJSE:870656) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Huayang Road, No. 36, High-tech Industrial Park, Zhejiang Province, Quzhou City, CHN
Zhejiang Chemsyn Pharm Co Ltd is engaged in research& development, production and sales of veterinary raw materials, pharmaceutical raw materials and intermediates. Its products category includes API, Sulfa API, Intermediates. It also includes N-Acetylsulfanilyl Chloride, Sulfanilamide, Sulfachloropyridazine Sodium, Sulfachloropyrazine Sodium.

Zhejiang Chemsyn Pharm Co (BJSE:870656) Headlines

No Headlines